Patents by Inventor Say-Jong Law

Say-Jong Law has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7875467
    Abstract: Chemiluminescent acridinium compounds are used in homogeneous assays to determine the concentration of an analyte in a sample without strong acid or strong base treatment. The chemiluminescent acridinium compounds include acridinium esters with electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus to inhibit pseudo-base formation, or acridinium sulfonamides with or without electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus.
    Type: Grant
    Filed: November 21, 2007
    Date of Patent: January 25, 2011
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Anand A. Natrajan, Todd Sells, Hartmut Schroeder, Guohan Yang, David Sharpe, Qingping Jiang, Hana Lukinsky, Say-Jong Law
  • Patent number: 7632928
    Abstract: An antibody and immunogen for generating an antibody to nitrofuran and/or nitrofuran metabolite such as tissue or protein bound nitrofuran metabolites. Nitrofurans and and/or nitrofuran metabolites in a biological sample can be detected by contacting the sample with the antibodies to form a complex that can be detected. The antibodies may also be incorporated into test kits for the detection of nitrofuran and/or nitrofuran metabolites.
    Type: Grant
    Filed: October 18, 2006
    Date of Patent: December 15, 2009
    Assignee: Charm Sciences, Inc
    Inventors: Say-Jong Law, Stanley E. Charm, Steven J. Saul
  • Patent number: 7611909
    Abstract: A method for the detection or quantitation of unlabeled target analyte in a biological sample, the method comprising labeling a target analyte for a biological sample suspected of containing unlabeled target analyte with an acridinium compound to form a labeled target analyte and providing the labeled target analyte to the biological sample, or providing the labeled target analyte to the biological sample, wherein the acridinium compound comprises an acridinium nucleus having an electron-donating substituent directly attached to the acridinium nucleus, with the electron-donating substituent attached at the C2 position. Chemiluminescent acridinium compounds useful in the method have emission maxima close to or in the near infrared (NIR) region (>590 nm).
    Type: Grant
    Filed: November 4, 2005
    Date of Patent: November 3, 2009
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Anand Natrajan, Qingping Jiang, David Sharpe, Say-Jong Law
  • Publication number: 20090029349
    Abstract: Chemiluminescent acridinium compounds are used in homogeneous assays to determine the concentration of an analyte in a sample without strong acid or strong base treatment. The chemiluminescent acridinium compounds include acridinium esters with electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus to inhibit pseudo-base formation, or acridinium sulfonamides with or without electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus.
    Type: Application
    Filed: November 21, 2007
    Publication date: January 29, 2009
    Applicant: Siemens Medical Solutions Diagnostics
    Inventors: Anand A. Natrajan, Todd Sells, Hartmut Schroeder, Guohan Yang, David Sharpe, Qingping Jiang, Hana Lukinsky, Say-Jong Law
  • Publication number: 20080305557
    Abstract: Chemiluminescent acridinium compounds are used in homogeneous assays to determine the concentration of an analyte in a sample without strong acid or strong base treatment. The chemiluminescent acridinium compounds include acridinium esters with electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus to inhibit pseudo-base formation, or acridinium sulfonamides with or without electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus.
    Type: Application
    Filed: November 21, 2007
    Publication date: December 11, 2008
    Applicant: Siemens Medical Solutions Diagnostics
    Inventors: Anand Natrajan, Todd Sells, Hartmut Schroeder, Guohan Yang, David Sharpe, Qingping Jiang, Hana Lukinsky, Say-Jong Law
  • Patent number: 7459284
    Abstract: A chemiluminescent substrate of a hydrolytic enzyme having the following general Formula I is disclosed, as follows: Lumi-M-P??Formula I where “Lumi” is a chemiluminescent moiety capable of producing light (a) by itself, (b) with MP attached and (c) with M attached. Examples of Lumi include chemiluminescent acridinium compounds, benzacridinium compounds, quinolinium compounds, isoquinolinium compounds, phenanthridinium compounds, and lucigenin compounds, spiroacridan compounds, luminol compounds and isoluminol compounds. M is a multivalent heteroatom having at least one lone pair of electrons selected from oxygen, nitrogen and sulfur, directly attached to the light emitting moiety of Lumi at one end and to P at the other end. P is a group that can be readily removed by hydrolytic enzymes. An enzymatic reaction utilizing the above compound is the following: where HE is a hydrolytic enzyme. Lumi-M is a chemiluminescent product having physical and/or chemical properties different from those of Lumi-M-P.
    Type: Grant
    Filed: June 5, 2006
    Date of Patent: December 2, 2008
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Qingping Jiang, Anand Natrajan, David Sharpe, Wen-Jee Wong, Say-Jong Law
  • Patent number: 7319041
    Abstract: Chemiluminescent acridinium compounds are used in homogeneous assays to determine the concentration of an analyte in a sample without strong acid or strong base treatment. The chemiluminescent acridinium compounds include acridinium esters with electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus to inhibit pseudo-base formation, or acridinium sulfonamides with or without electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: January 15, 2008
    Assignee: Siemens Medical Solutions Diagnostic
    Inventors: Anand Natrajan, Todd Sells, Hartmut Schroeder, Guohan Yang, David Sharpe, Qingping Jiang, Hana Lukinsky, Say-Jong Law
  • Publication number: 20070054340
    Abstract: An antibody and immunogen for generating an antibody to nitrofuran and/or nitrofuran metabolite such as tissue or protein bound nitrofuran metabolites. Nitrofurans and and/or nitrofuran metabolites in a biological sample can be detected by contacting the sample with the antibodies to form a complex that can be detected. The antibodies may also be incorporated into test kits for the detection of nitrofuran and/or nitrofuran metabolites.
    Type: Application
    Filed: October 18, 2006
    Publication date: March 8, 2007
    Inventors: Say-Jong Law, Stanley Charm, Steven Saul
  • Publication number: 20060202179
    Abstract: A chemiluminescent substrate of a hydrolytic enzyme having the following general Formula I is disclosed, as follows: Lumi-M-P ??Formula I where “Lumi” is a chemiluminescent moiety capable of producing light (a) by itself, (b) with MP attached and (c) with M attached. Examples of Lumi include chemiluminescent acridinium compounds, benzacridinium compounds, quinolinium compounds, isoquinolinium compounds, phenanthridinium compounds, and lucigenin compounds, spiroacridan compounds, luminol compounds and isoluminol compounds. M is a multivalent heteroatom having at least one lone pair of electrons selected from oxygen, nitrogen and sulfur, directly attached to the light emitting moiety of Lumi at one end and to P at the other end. P is a group that can be readily removed by hydrolytic enzymes. An enzymatic reaction utilizing the above compound is the following: where HE is a hydrolytic enzyme. Lumi-M is a chemiluminescent product having physical and/or chemical properties different from those of Lumi-M-P.
    Type: Application
    Filed: June 5, 2006
    Publication date: September 14, 2006
    Applicant: BAYER CORPORATION
    Inventors: Qingping Jiang, Anand Natrajan, David Sharpe, Wen-Jee Wong, Say-Jong Law
  • Patent number: 7097995
    Abstract: A chemiluminescent substrate of a hydrolytic enzyme having the following general Formula I is disclosed, as follows: Lumi-M-PFormula I where “Lumi” is a chemiluminescent moiety capable of producing light (a) by itself, (b) with MP attached and (c) with M attached. Examples of Lumi include chemiluminescent acridinium compounds, benzacridinium compounds, quinolinium compounds, isoquinolinium compounds, phenanthridinium compounds, and lucigenin compounds, spiroacridan compounds, luminol compounds and isoluminol compounds. M is a multivalent heteroatom having at least one lone pair of electrons selected from oxygen, nitrogen and sulfur, directly attached to the light emitting moiety of Lumi at one end and to P at the other end. P is a group that can be readily removed by hydrolytic enzymes. An enzymatic reaction utilizing the above compound is the following: where HE is a hydrolytic enzyme. Lumi-M is a chemiluminescent product having physical and/or chemical properties different from those of Lumi-M-P.
    Type: Grant
    Filed: August 27, 2004
    Date of Patent: August 29, 2006
    Assignee: Bayer Corp.
    Inventors: Qingping Jiang, Anand Natrajan, David J. Sharpe, Wen-Jee Wong, Say-Jong Law
  • Patent number: 7083986
    Abstract: A method for the detection or quantitation of an analyte in a biological sample is disclosed. The method comprises the steps of selecting a biological sample suspected of containing a target analyte and binding the target analyte in the sample to a binding partner conjugated to an acridinium compound, wherein the acridinium compound comprises an acridinium nucleus having an electron-donating substituent directly attached to the acridinium nucleus at the C2 position. Chemiluminescent acridinium compounds useful in the method have emission maxima close to or in the near infrared (NIR) region (>590 nm). These chemiluminescent acridinium compounds when used in conjunction with short wavelength-emitting acridinium esters (with emission maxima below 450 nm) can be highly useful labels for the simultaneous detection of multiple target analytes in a single assay.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: August 1, 2006
    Assignee: Bayer Healthcare LLC
    Inventors: Anand Natrajan, Qingping Jiang, David Sharpe, Say-Jong Law
  • Publication number: 20050032147
    Abstract: A chemiluminescent substrate of a hydrolytic enzyme having the following general Formula I is disclosed, as follows: Lumi-M-P??Formula I where “Lumi” is a chemiluminescent moiety capable of producing light (a) by itself, (b) with MP attached and (c) with M attached. Examples of Lumi include chemiluminescent acridinium compounds, benzacridinium compounds, quinolinium compounds, isoquinolinium compounds, phenanthridinium compounds, and lucigenin compounds, spiroacridan compounds, luminol compounds and isoluminol compounds. M is a multivalent heteroatom having at least one lone pair of electrons selected from oxygen, nitrogen and sulfur, directly attached to the light emitting moiety of Lumi at one end and to P at the other end. P is a group that can be readily removed by hydrolytic enzymes. An enzymatic reaction utilizing the above compound is the following: where HE is a hydrolytic enzyme. Lumi-M is a chemiluminescent product having physical and/or chemical properties different from those of Lumi-M-P.
    Type: Application
    Filed: August 27, 2004
    Publication date: February 10, 2005
    Inventors: Qingping Jiang, Anand Natrajan, David Sharpe, Wen-Jee Wong, Say-Jong Law
  • Patent number: 6783948
    Abstract: A chemiluminescent substrate of hydrolytic enzyme having the following general Formula I, as follows: Lumi-M-P  Formula I where “Lumi” is a chemiluminescent moiety capable of producing light (a) by itself, (b) with MP attached and (c) with M attached. Examples of Lumi include chemiluminescent acridinium compounds, benzacridinium compounds, quinolinium compounds, isoquinolinium compounds, phenanthridinium compounds, and lucigenin compounds, spiroacridan compounds, luminol compounds and isoluminol compounds. M is a multivalent heteroatom having at least one lone pair of electrons selected from oxygen, nitrogen and sulfur, directly attached to the light emitting moiety of Lumi at one end and to P at the other end. P it a group that can be readily removed by hydrolytic enzymes.
    Type: Grant
    Filed: July 27, 2000
    Date of Patent: August 31, 2004
    Assignee: Bayer Corporation
    Inventors: Qingping Jiang, Anand Natrajan, David J. Sharpe, Wen-Jee Wong, Say-Jong Law
  • Publication number: 20040063147
    Abstract: Chemiluminescent acridinium compounds are used in homogeneous assays to determine the concentration of an analyte in a sample without strong acid or strong base treatment. The chemiluminescent acridinium compounds include acridinium esters with electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus to inhibit pseudo-base formation, or acridinium sulfonamides with or without electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus.
    Type: Application
    Filed: September 27, 2002
    Publication date: April 1, 2004
    Applicant: BAYER CORPORATION
    Inventors: Anand Natrajan, Todd Sells, Hartmut Schroeder, Guohan Yang, David Sharpe, Qingping Jiang, Hana Lukinsky, Say-Jong Law
  • Patent number: 6673560
    Abstract: The present invention discloses a method for the measurement of hydride using a chemiluminescent compound. The preferred chemiluminescent molecule is an acridinium compound. The source of hydride for the reduction of acridinium compound may be of chemical or biochemical origin, or the result of enzymatic catalysis. The chemical source of hydride, for example, might be metal hydrides, such as NaBH4. A biochemical source of hydride might be that derived from NADH, or NADPH, while an enzymatic source would be the class of oxidoreductases termed dehydrogenases which convert NADH or NADPH from NAD or NADP. There are numerous potential applications for acridinium compounds as chemiluminescent indicators of hydride. Any applied tests or diagnostic assays, in which hydride is either present at the onset of or generated through the course of a reaction, would benefit from the present invention.
    Type: Grant
    Filed: November 23, 1999
    Date of Patent: January 6, 2004
    Assignee: Bayer Corporation
    Inventors: David Sharpe, Anand Natrajan, Qingping Jiang, George Parsons, Say-Jong Law
  • Publication number: 20030143607
    Abstract: Highly hydrophilic non-nucleosidic tags with multiple labels are provided for use in nucleic acid probes. The tags are branched structures having a phosphodiester backbone, which have the advantages of a small dimensional size and high hydrophilicity. After the tag is labeled, its high negative charge and minimal size help to keep the carriers away from DNA or RNA molecules, due to repulsion between negative charges. Non-specific intercalation and steric hindrance are therefore minimized, and the hydrophobicity, if any of reporter molecules is reduced. The probes are used in place of conventionally labeled oligonucleotides for a variety of hybridization reactions.
    Type: Application
    Filed: December 18, 2002
    Publication date: July 31, 2003
    Inventors: Guohan Yang, Donna M. Ford, Say-Jong Law, John E. Monahan, Todd B. Sells
  • Patent number: 6504019
    Abstract: Highly hydrophilic non-nucleosidic tags with multiple labels are provided for use in nucleic acid probes. The tags are branched structures having a phosphodiester backbone, which have the advantages of a small dimensional size and high hydrophilicity. After the tag is labeled, its high negative charge and minimal size help to keep the carriers away from DNA or RNA molecules, due to repulsion between negative charges. Non-specific intercalation and steric hindrance are therefore minimized, and the hydrophobicity, if any of reporter molecules is reduced. The probes are used in place of conventionally labeled oligonucleotides for a variety of hybridization reactions.
    Type: Grant
    Filed: March 21, 2001
    Date of Patent: January 7, 2003
    Assignee: Bayer Corporation
    Inventors: Guohan Yang, Donna M. Ford, Say-Jong Law, John E. Monahan, Todd B. Sells
  • Patent number: 6465175
    Abstract: Methods are provided for reducing background signals encountered in nucleic acid hybridization assays and other assays that involve hybridization of a labeled oligomer to its complement. The method is premised on the significant reduction of signal generation that occurs when a quenchable dye-labeled oligomer forms a hybrid complex. In addition, a method is provided for enhancing the detectable signal emitted from an amplification multimer hybridized to an oligomer probe to which a quenchable dye has been conjugated through a linker such that the emission from the dye is not quenched upon hybrid complex formation. Novel oligonucleotide probes are also provided that comprise an oligomer to which has been directly or indirectly through a linker a quenchable dye.
    Type: Grant
    Filed: September 3, 1998
    Date of Patent: October 15, 2002
    Assignee: Bayer Corporation
    Inventors: Thomas Horn, Hartmut R. Schroeder, Brian D. Warner, Ellen Fiss, Todd Sells, Say-Jong Law
  • Publication number: 20020098485
    Abstract: Disclosed is amplification of a target sequence using the activity of a replicase that quasi-autocatalytically replicates a specific replicase replicable or “replicatable” sequence, while ensuring fidelity thereof by detecting the presence of the amplified target or antitarget sequence rather than the amplified replicase replicable sequence. A method according to the invention for assaying a target nucleic acid comprising hybridizing a set of one or more amplification probes with a nucleic acid sample is provided. A set of two chemiluminescent detection probes each for detecting portions of amplified target sequence along with a dual photomultiplier tube detection system for simultaneous detection of the two chemiluminescent detection probes are also provided for practicing the invention, for use with a target specific set of amplification probes. Kits for practicing the invention are also provided.
    Type: Application
    Filed: February 8, 2001
    Publication date: July 25, 2002
    Inventors: Ann M. Morello, Qingping Jiang, John E. Monahan, Say-Jong Law
  • Publication number: 20020076823
    Abstract: Our results thus identify two sets of necessary and sufficient criteria for observing long-wavelength emission from acridinium compounds:
    Type: Application
    Filed: December 6, 2001
    Publication date: June 20, 2002
    Applicant: BAYER CORPORATION
    Inventors: Anand Natrajan, Qingping Jiang, David Sharpe, Say-Jong Law